Disitamab vedotin

Disitamab vedotin (trade name Aidixi) is a drug for the treatment of various types of solid tumors. It is an antibody-drug conjugate that consists of an immunoglobulin G1 antibody that is linked to the antitumor agent vedotin (monomethyl auristatin E).

Background
In China, disitamab vedotin was approved in 2021 for the treatment of patients with HER2-overexpressing locally advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, who have received at least two systemic chemotherapy regimens. In the United States, the FDA has granted disitamab vedotin a breakthrough therapy designation for the treatment of patients with HER2-positive locally advanced or metastatic urothelial carcinoma following treatment with platinum-based chemotherapy.